ProKidney

Rilparencel is an investigational cell therapy designed to stabilize kidney function and delay dialysis in advanced CKD patients.

ProKidney invites physicians to join clinical trials as principal investigators and directs patients to clinicaltrials.gov.

ProKidney invites physicians to express interest in becoming principal investigators for ongoing clinical trials.

ProKidney provides cGMP-compliant cell therapy manufacturing and quality assurance in North Carolina, USA.

ProKidney presented non-clinical data on rilparencel’s manufacturing process at the American Society of Nephrology Kidney Week 2026.

The Associate Director of Quality Control oversees quality control operations and batch release for ProKidney’s clinical trial materials.

ProKidney’s technology uses a patient’s own kidney cells to treat chronic kidney disease and potentially delay dialysis.

The Director of Quality Assurance leads quality operations and batch release activities for ProKidney’s clinical trial materials.

The Enterprise Applications Administrator maintains ERP systems, user access, and technology-related training at ProKidney.

The ProKidney team averages more than twenty years of experience, with over 150 years cumulative experience in the discovery, development, manufacturing and commercialization of biotechnology, pharmaceutical, and device products.

ProKidney’s Patient Advisory Board includes individuals with Chronic Kidney Disease (CKD) who advise on clinical trials.

ProKidney develops rilparencel, an autologous cell therapy for chronic kidney disease, to preserve kidney function and delay dialysis.

Kevin Fowler has over 25 years of experience in pharmaceutical sales, marketing, and patient advocacy.

ProKidney’s offices are located in Winston-Salem, NC, and Boston, MA, with contact details for inquiries.

ProKidney’s headquarters is located at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103.

ProKidney develops an autologous cell therapy to preserve kidney function in patients with advanced chronic kidney disease at high risk of kidney failure.

[cmplz-document type=”cookie-statement” region=”eu”]

ProKidney is developing rilparencel for chronic kidney disease and type 2 diabetes mellitus, focusing on clinical development.

ProKidney Corp. presents mechanism of action data from its ASN Kidney Week findings in a virtual key opinion leader (KOL) event. The late-stage cell therapy company also delivers a corporate update on its chronic kidney disease (CKD) research. The event targets medical experts and stakeholders to discuss clinical progress and company developments.

Oct 2026ProKidneyNews article

ProKidney presents eight research abstracts, including one oral session, at the **American Society of Nephrology’s Kidney Week 2026** in Denver. The company’s submissions focus on its late-stage cell therapy advancements for **chronic kidney disease (CKD)**. The event runs from **October 21–25, 2026**, showcasing ProKidney’s clinical-stage research in nephrology.

Oct 2026ProKidneyNews article

ProKidney Corp. reports second-quarter 2026 financial results, highlighting its late-stage cell therapy development for chronic kidney disease (CKD). The company provides updates on its clinical progress and operational performance as it advances treatments targeting kidney failure patients. ProKidney remains focused on translating its research into potential therapies for a high-unmet-need market.

Aug 2026ProKidneyNews article

ProKidney Corp. names **Kenneth Locke** as its new **Chief Technical Officer**, bringing expertise in scaling advanced therapy platforms and executing complex manufacturing strategies. The late clinical-stage cell therapy company focuses on treating chronic kidney disease (CKD). Locke’s appointment aligns with ProKidney’s preparations for pivotal trials in its pipeline.

Jun 2026ProKidneyNews article